DGIdb - TRIFLUOPERAZINE Drug Record

TRIFLUOPERAZINE chembl:CHEMBL422 Approved

Alternate Names:

STELAZINE
STELAZINE FTE
AMYLOZINE
TRIFLUOPERAZINE
ESKAZINYL®
10-[3-(4-METHYL-1-PIPERAZINYL)PROPYL]-2-(TRIFLUOROMETHYL)-10H-PHENOTHIAZINE
STELAZINE®
TRIFLUPERAZINE
TRIFLUOPERAZINA
TRIFLUOROMETHYL-10-(3'-(1-METHYL-4-PIPERAZINYL)PROPYL)PHENOTHIAZINE
10-[3-(4-METHYL-PIPERAZIN-1-YL)-PROPYL]-2-TRIFLUOROMETHYL-10H-PHENOTHIAZINE
TRIFLUOROPERAZINE
TRIFLUOPERAZINE HYDROCHLORIDE
TRIFLUOPERAZINUM
pubchem.compound:5566
chemidplus:117-89-5
rxcui:10800
chembl:CHEMBL422
drugbank:00831

Drug Info:

Drug Class	antipsychotic agents
Year of Approval	1959
Drug Class	antiemetics
FDA Approval	1959
Drug Class	small molecule
Drug Indications	Antipsychotic Agents
Drug Indications	Antiemetics

(3 More Sources)

Publications:

Fan et al., 2005, G protein-coupled receptor activation rapidly stimulates focal adhesion kinase phosphorylation at Ser-843. Mediation by Ca2+, calmodulin, and Ca2+/calmodulin-dependent kinase II., J. Biol. Chem.
Seeman et al., 1976, Antipsychotic drug doses and neuroleptic/dopamine receptors., Nature
Madrid et al., 2007, Synthesis and antitubercular activity of phenothiazines with reduced binding to dopamine and serotonin receptors., Bioorg. Med. Chem. Lett.
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Sullivan et al., Augmentation of apoptosis by the combination of bleomycin with trifluoperazine in the presence of mutant p53., J. Exp. Ther. Oncol.
Tay JK et al., 2007, Functional polymorphisms of the cytochrome P450 1A2 (CYP1A2) gene and prolonged QTc interval in schizophrenia., Prog Neuropsychopharmacol Biol Psychiatry
Lahti et al., 1993, Dopamine D4 versus D2 receptor selectivity of dopamine receptor antagonists: possible therapeutic implications., Eur. J. Pharmacol.
Schmidt et al., 1991, Investigation of striatal dopamine D2 receptor acquisition following prenatal neuroleptic exposure., Psychiatry Res
Seeman, 2002, Atypical antipsychotics: mechanism of action., Can J Psychiatry
Cahir et al., 2005, Antipsychotics lack alpha 1A/B adrenoceptor subtype selectivity in the rat., Eur Neuropsychopharmacol
Porcelli S et al., 2016, PDE7B, NMBR and EPM2A Variants and Schizophrenia: A Case-Control and Pharmacogenetics Study., Neuropsychobiology
Kastrinsky DB et al., 2015, Reengineered tricyclic anti-cancer agents., Bioorg Med Chem
Mohindroo et al., 1997, Effect of trifluoperazine on certain arterial wall lipid-metabolizing enzymes inducing atherosclerosis in rhesus monkeys., Lipids
Huerta-Bahena et al., 1983, Trifluoperazine and chlorpromazine antagonize alpha 1- but not alpha2- adrenergic effects., Mol. Pharmacol.
Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
Fujinaga et al., 1994, Receptor subtype and intracellular signal transduction pathway associated with situs inversus induced by alpha 1 adrenergic stimulation in rat embryos., Dev. Biol.
Field et al., 1995, Esterification of plasma membrane cholesterol and triacylglycerol-rich lipoprotein secretion in CaCo-2 cells: possible role of p-glycoprotein., J. Lipid Res.
Katayama et al., 1990, A role for calmodulin in the growth of human hematopoietic progenitor cells., Blood

TRIFLUOPERAZINE CALY

Interaction Score: 6.44

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
945467 17407813 11752352

Sources:
TdgClinicalTrial TEND
TRIFLUOPERAZINE LIPA

Interaction Score: 1.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9270979

Sources:
NCI
TRIFLUOPERAZINE EPM2A

Interaction Score: 0.74

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27092952

Sources:
PharmGKB
TRIFLUOPERAZINE APOB

Interaction Score: 0.29

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
7595077

Sources:
NCI
TRIFLUOPERAZINE CAMK2B

Interaction Score: 0.27

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15845548

Sources:
NCI
TRIFLUOPERAZINE ADRA1A

Interaction Score: 0.18

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
6135146 17016423 17139284 8150214

Sources:
TdgClinicalTrial TEND
TRIFLUOPERAZINE CSF2

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
1690578

Sources:
NCI
TRIFLUOPERAZINE DRD2

Interaction Score: 0.12

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
8102973 945467 1676523 11873706 15695070 11752352

Sources:
TdgClinicalTrial TEND
TRIFLUOPERAZINE AKT1

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26372073

Sources:
DTC
TRIFLUOPERAZINE THPO

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
TRIFLUOPERAZINE RAD52

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
TRIFLUOPERAZINE RGS4

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
TRIFLUOPERAZINE TP53

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12415616

Sources:
DTC NCI
TRIFLUOPERAZINE GLP1R

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
TRIFLUOPERAZINE DRD1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
TRIFLUOPERAZINE MAPK1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
TRIFLUOPERAZINE CBX1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
TRIFLUOPERAZINE CYP1A2

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17611010

Sources:
DTC PharmGKB
TRIFLUOPERAZINE USP1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
TRIFLUOPERAZINE ATXN2

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
TRIFLUOPERAZINE CYP2C19

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
TRIFLUOPERAZINE CYP2D6

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
TRIFLUOPERAZINE EHMT2

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
TRIFLUOPERAZINE CYP3A4

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

TEND: TRIFLUOPERAZINE
- Version: 01-August-2011
Alternate Names:

TRIFLUOPERAZINE Primary Drug Name

Drug Info:

Drug Class antiemetics

Year of Approval 1959

Drug Class antipsychotic agents

Publications:
TdgClinicalTrial: TRIFLUOPERAZINE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications Antiemetics

Drug Indications Antipsychotic Agents

Drug Class small molecule

Publications:
DTC: TRIFLUOPERAZINE
- Version: 02-September-2020
Alternate Names:

CHEMBL422 ChEMBL Drug ID

Drug Info:

Publications:

Kastrinsky DB et al., 2015, Reengineered tricyclic anti-cancer agents., Bioorg Med Chem

NCI: TRIFLUOPERAZINE

Version: 14-September-2017

Alternate Names:

C904 NCI drug code

Drug Info:

Publications:

Mohindroo et al., 1997, Effect of trifluoperazine on certain arterial wall lipid-metabolizing enzymes inducing atherosclerosis in rhesus monkeys., Lipids

Katayama et al., 1990, A role for calmodulin in the growth of human hematopoietic progenitor cells., Blood

Fan et al., 2005, G protein-coupled receptor activation rapidly stimulates focal adhesion kinase phosphorylation at Ser-843. Mediation by Ca2+, calmodulin, and Ca2+/calmodulin-dependent kinase II., J. Biol. Chem.

PharmGKB: trifluoperazine

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Tay JK et al., 2007, Functional polymorphisms of the cytochrome P450 1A2 (CYP1A2) gene and prolonged QTc interval in schizophrenia., Prog Neuropsychopharmacol Biol Psychiatry

Porcelli S et al., 2016, PDE7B, NMBR and EPM2A Variants and Schizophrenia: A Case-Control and Pharmacogenetics Study., Neuropsychobiology

TTD: Trifluoperazine
- Version: 2020.06.01
Alternate Names:

D0R4OM TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL422
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:

Trial Name	-
Novel drug target	Established target

Trial Name	-
Novel drug target	Established target

Trial Name	-
Novel drug target	Established target

TRIFLUOPERAZINE Drug Record

TRIFLUOPERAZINE chembl:CHEMBL422 Approved

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info: Trial Name - Novel drug target Established target

PMIDs: 945467 17407813 11752352

Sources: TdgClinicalTrial TEND

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 9270979

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27092952

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 7595077

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15845548

Sources: NCI

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info: Trial Name - Novel drug target Established target

PMIDs: 6135146 17016423 17139284 8150214

Sources: TdgClinicalTrial TEND

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 1690578

Sources: NCI

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info: Trial Name - Novel drug target Established target

PMIDs: 8102973 945467 1676523 11873706 15695070 11752352

Sources: TdgClinicalTrial TEND

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26372073

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 12415616

Sources: DTC NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17611010

Sources: DTC PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
945467 17407813 11752352

Sources:
TdgClinicalTrial TEND

Interaction Types & Directionality:

n/a

PMIDs:
9270979

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
27092952

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
7595077

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
15845548

Sources:
NCI

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
6135146 17016423 17139284 8150214

Sources:
TdgClinicalTrial TEND

Interaction Types & Directionality:

n/a

PMIDs:
1690578

Sources:
NCI

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
8102973 945467 1676523 11873706 15695070 11752352

Sources:
TdgClinicalTrial TEND

Interaction Types & Directionality:

n/a

PMIDs:
26372073

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
12415616

Sources:
DTC NCI

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
17611010

Sources:
DTC PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Alternate Names:

TRIFLUOPERAZINE Primary Drug Name

Drug Info:

Drug Class antiemetics

Year of Approval 1959

Drug Class antipsychotic agents

Drug Info:

Drug Indications Antiemetics

Drug Indications Antipsychotic Agents

Drug Class small molecule

Alternate Names:

CHEMBL422 ChEMBL Drug ID

Publications:

Kastrinsky DB et al., 2015, Reengineered tricyclic anti-cancer agents., Bioorg Med Chem